⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887775 | 0.60 | — | — | |
| SCHEMBL14403170 | 0.60 | — | — | |
| SCHEMBL11481715 | 0.58 | — | — | |
| SCHEMBL14859331 | 0.56 | — | — | |
| SCHEMBL1358214 | 0.55 | KDM4E (0.37) | — | |
| SCHEMBL17294071 | 0.55 | KDM4E (0.37) | — | |
| SCHEMBL3132852 | 0.55 | — | — | |
| SCHEMBL10882028 | 0.55 | — | — | |
| SCHEMBL11405480 | 0.54 | PKM (0.44) | — | |
| SCHEMBL8941008 | 0.54 | PKM (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290444-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150265613-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC (US) | 2015-09-24 | — | — | US | disclosed |
| US-8993632-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20150065508-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-8716345-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBVIE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130045978-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBVIE INC. | 2013-02-21 | — | — | US | disclosed |
| US-8314270-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-11-20 | — | — | US | disclosed |
| US-20120289512-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-11-15 | — | — | US | disclosed |
| US-8198331-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-06-12 | — | — | US | disclosed |
| US-20110218214-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2011-09-08 | — | — | US | disclosed |
| US-7855308-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2010-12-21 | — | — | US | disclosed |
| US-RE41135-E1 | Inhibitors of the 11-β-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090192198-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-30 | — | — | US | disclosed |
| US-20090176783-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090131434-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2009-05-21 | — | — | US | disclosed |
| US-7528282-B2 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBOTT LABORATORIES (US) | 2009-05-05 | — | — | US | disclosed |
| US-7511175-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme | ABBOTT LABORATORIES (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070179186-A1 | for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and conditions because of excessive glucocorticoid action; E-4-(2-methyl-2-phenoxy-propionylamino)-adamantane-1-carboxylic acid amide | ABBVIE INC. | 2007-08-02 | — | — | US | disclosed |
| US-7217838-B2 | Compounds such as E-4-{[1-(4-Chloro-phenyl)-cyclobutanecarbonyl]-amino}-adamantane-1-carboxylic acid; fortherapy of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and diseases and conditions that are mediated by excessive glucocorticoid action | ABBOTT LABORATORIES (US) | 2007-05-15 | — | — | US | disclosed |